Related Experiment Videos
Thrombolysis for acute deep vein thrombosis
1Cochrane PVD Group, University of Edinburgh, Dept of Public Health Sciences, Teviot Place, Edinburgh, UK, EH3 9AG. lorna.watson@isd.csa.scot.nhs.uk
The Cochrane Database of Systematic Reviews
|October 21, 2004
Summary
Thrombolysis effectively dissolves deep vein thrombosis (DVT) clots, reducing long-term post-thrombotic syndrome and improving venous patency. While increasing bleeding risks, strict criteria enhance safety for DVT treatment.
Area of Science:
- Vascular Medicine
- Interventional Cardiology
- Hematology
Background:
- Standard deep vein thrombosis (DVT) treatment focuses on immediate complication reduction.
- Thrombolysis, or clot-dissolving drugs, may mitigate long-term post-thrombotic syndrome (PTS) complications.
- PTS can manifest as pain, swelling, skin discoloration, or venous ulceration in affected limbs.
Purpose of the Study:
- To evaluate the efficacy of thrombolysis in treating DVT.
- To assess the safety profile of thrombolysis for DVT.
- To determine the impact of thrombolysis on long-term DVT complications.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) comparing thrombolysis with anticoagulation for acute DVT.
- Searches conducted in the Cochrane Peripheral Vascular Diseases trials register and CENTRAL database up to April 2004.
- Data extraction and quality assessment performed by two independent reviewers.
Main Results:
- Thrombolysis significantly increased complete clot lysis in early and late follow-up periods.
- Improved venous patency and reduced incidence of post-thrombotic syndrome were observed with thrombolysis.
- Increased bleeding complications were noted, but the incidence of leg ulceration was reduced; stroke and mortality data were inconclusive.
Conclusions:
- Thrombolysis offers significant benefits in reducing post-thrombotic syndrome and enhancing venous patency post-DVT.
- Implementing strict eligibility criteria has improved the safety and tolerability of thrombolysis.
- Further research is needed to determine optimal thrombolytic agents, dosages, and administration routes.